Stelzer D, et al. - A comparative scrutiny was conducted of the clinical effectiveness, toxicity, and pharmacokinetics of Posaconazole oral suspension (POS-Liq)-Liq with delayed-release tablets (POS-Tab) in lung transplant recipients (LTx-recipients), who were treated with both formulations subsequently. POS-Tab was recommended for prophylaxis and therapy of Aspergillus infections in LTx-recipients, due to POS-Tab being more reliable posaconazole trough levels (PTLs) with no added adverse events. Regular drug monitoring was, however, suggested for POS-Liq and for therapy with POS-Tab and that immunosuppressant levels, along with close monitoring when the posaconazole formulation was switched.